Related references
Note: Only part of the references are listed.Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Monique Terwijn et al.
PLOS ONE (2014)
CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia
Harry Dang et al.
HUMAN PATHOLOGY (2013)
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation
Hong-Hu Zhu et al.
LEUKEMIA RESEARCH (2013)
Normal Hematopoietic Stem Cells within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level than Co-Existing Leukemic Stem Cells
Gerrit J. Schuurhuis et al.
PLOS ONE (2013)
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
Thomas Pabst et al.
BLOOD (2012)
The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse
C. Bachas et al.
LEUKEMIA (2012)
Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers
Veronika Rockova et al.
BLOOD (2011)
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms
Gert J. Ossenkoppele et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Nicolas Goardon et al.
CANCER CELL (2011)
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
Francois Vergez et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R gamma c-deficient mice
Jean-Emmanuel Sarry et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice
Maria Paola Martelli et al.
BLOOD (2010)
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction
David C. Taussig et al.
BLOOD (2010)
Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies
Maria Diez-Campelo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes
Dan Ran et al.
EXPERIMENTAL HEMATOLOGY (2009)
Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia
Luca Maurillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
Fumihiko Ishikawa et al.
NATURE BIOTECHNOLOGY (2007)
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age
Marry M. van den Heuvel-Eibrink et al.
ANNALS OF HEMATOLOGY (2007)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia
N Feller et al.
LEUKEMIA (2004)
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias
Z Benderra et al.
CLINICAL CANCER RESEARCH (2004)
CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes
L Suárez et al.
CLINICAL CANCER RESEARCH (2004)
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia
W Kern et al.
BLOOD (2004)
Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis
MA van der Pol et al.
LEUKEMIA (2003)
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
ML Guzman et al.
BLOOD (2001)
Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification
JF San Miguel et al.
BLOOD (2001)
Share Paper
